Abstract
Evaluation of costs associated with a medical condition and cost effectiveness of therapy do not usually take into account the indirect harm that the condition causes in terms of deterioration of the quality of life. Febrile neutropenia (FN) is an illness requiring antimicrobial therapy and possible hospitalization, often disturbing the familial and social life; it may lead to reduction, delay, or even discontinuation of effective chemotherapy, causing thus a direct prejudice to the patient’s health.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Michels SL, Barron RL, Reynolds MW, Smoyer Tomic K, Yu J, Lyman GH. Costs associated with febrile neutropenia in the US. Pharmacoeconomics. 2012;30:809-823.
Schilling MB, Parks C, Deeter RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med. 2011;2:859-866.
Lyman GH, Kuderer N, Greene J, Balducci L. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer. 1998;34;1857-1864.
Hirsch BR, Lyman GH. Pharmacoeconomics of the myeloid growth factors. A critical and systematic review. Pharmacoeconomics. 2012;30:497-511.
Lingaratnam S, Worth LJ, Slavin MA, et al. A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment. Aust Health Rev. 2011;35:491-500.
Aapro MS, Bohlius J, Cameron DA, et al; European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8-32.
Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158-3167.
Papaldo P, Lopez M, Marolla P, et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubin and cyclophosphamide. J Clin Oncol. 2005;23:6908-6918.
Klastersky J, Awada A, Aoun M, Paesmans M. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended? Curr Opin Oncol. 2009;21:297-302.
Klastersky J, Georgala A, Ameye L, et al. Febrile neutropenia occurring in patients with solid tumors: is the risk of complications affected by the type of chemotherapy? Support Care Cancer. 2010;18(Suppl 3):S101-S102.
Hadji P, Kostev K, Schröder-Bernhardi D, Ziller V. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany. Int J Clin Pharmacol Ther. 2012;50:281-289.
Klastersky JA, Paesmans M. Treatment of febrile neutropenia is expensive: prevention is the answer. Onkologie. 2011;34:226-228.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2014 Springer Healthcare
About this chapter
Cite this chapter
Klastersky, J.A. (2014). Costs Associated with Febrile Neutropenia. In: Febrile Neutropenia. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-907673-70-2_7
Download citation
DOI: https://doi.org/10.1007/978-1-907673-70-2_7
Published:
Publisher Name: Springer Healthcare, Tarporley
Print ISBN: 978-1-907673-69-6
Online ISBN: 978-1-907673-70-2
eBook Packages: MedicineMedicine (R0)